Research Topics
| Maddalena BarbaSummaryAffiliation: Regina Elena Cancer Institute Country: Italy Publications
| Collaborators
|
Detail Information
Publications
Perinatal exposures and breast cancer risk in the Western New York Exposures and Breast Cancer (WEB) StudyMaddalena Barba
Department of Social and Preventive Medicine, School of Public Health and Health Professions, University at Buffalo, Buffalo, NY, USA
Cancer Causes Control 17:395-401. 2006..There is increasing evidence that early life exposures, such as birth weight, infant feeding practices, birth rank and maternal age at delivery may play a role in breast carcinogenesis...
Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer: a systematic reviewElie A Akl
Department of Medicine, State University of New York at Buffalo, Buffalo, New York 14215, USA
Cancer 113:1685-94. 2008..The authors compared the relative efficacy and safety of low-molecular-weight heparin (LMWH) and unfractionated heparin (UFH) for the initial treatment of venous thromboembolism (VTE) between patients with and without cancer...- Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulationElie A Akl
Department of Medicine, State University of New York at Buffalo, ECMC CC 142, 462 Grider Street, Buffalo, NY, USA, 14215
Cochrane Database Syst Rev 4:CD006652. 2011..Anticoagulation may improve survival in patients with cancer through an antitumor effect in addition to the perceived antithrombotic effect... 
Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic reviewElie A Akl
Department of Medicine, State University of New York at Buffalo, Buffalo, NY, USA
J Exp Clin Cancer Res 27:21. 2008..The objective of this study was to compare low molecular weight heparin (LMWH) and oral anticoagulants (vitamin K antagonist (VKA) and ximelagatran) for the long term treatment of venous thromboembolism in patients with cancer...- Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulationElie A Akl
Department of Medicine, State University of New York at Buffalo, ECMC CC 142, 462 Grider Street, Buffalo, NY, USA, 14215
Cochrane Database Syst Rev 1:CD006652. 2011..Anticoagulation may improve survival in patients with cancer through an antitumor effect in addition to the perceived antithrombotic effect... - Extended perioperative thromboprophylaxis in patients with cancer. A systematic reviewElie A Akl
Department of Medicine, State University of New York at Buffalo, ECMC CC 142, 462 Grider St, Buffalo, NY 14215, USA
Thromb Haemost 100:1176-80. 2008..More and better quality evidence is needed to justify extended regimens... - Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancerElie A Akl
Department of Medicine, State University of New York at Buffalo, ECMC CC 142, 462 Grider Street, Buffalo, NY, USA, 14215
Cochrane Database Syst Rev 11:CD009447. 2011..The choice of the appropriate perioperative thromboprophylaxis in patients with cancer depends on the relative benefits and harms of low molecular weight heparin (LMWH) and unfractionated heparin (UFH)... - Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulationElie A Akl
Department of Medicine, State University of New York at Buffalo, ECMC CC 142, 462 Grider Street, Buffalo, NY, USA, 14215
Cochrane Database Syst Rev 6:CD006466. 2011..A number of basic research and clinical studies have led to the hypothesis that oral anticoagulants may improve the survival of patients with cancer through an antitumor effect in addition to their antithrombotic effect... - Anticoagulation for the initial treatment of venous thromboembolism in patients with cancerElie A Akl
Department of Medicine, State University of New York at Buffalo, ECMC CC 142, 462 Grider Street, Buffalo, NY, USA, 14215
Cochrane Database Syst Rev 6:CD006649. 2011..Compared to patients without cancer, patients with cancer who receive anticoagulant treatment for venous thromboembolism are more likely to develop recurrent venous thromboembolism (VTE)... - Anticoagulation for the initial treatment of venous thromboembolism in patients with cancerElie A Akl
Department of Medicine, State University of New York at Buffalo, ECMC CC 142, 462 Grider Street, Buffalo, NY, USA, 14215
Cochrane Database Syst Rev 4:CD006649. 2011..Compared to patients without cancer, patients with cancer who receive anticoagulant treatment for venous thromboembolism are more likely to develop recurrent venous thromboembolism (VTE)... - Anticoagulation for patients with cancer and central venous cathetersElie A Akl
Department of Medicine, State University of New York at Buffalo, ECMC CC 142, 462 Grider Street, Buffalo, NY, USA, 14215
Cochrane Database Syst Rev 4:CD006468. 2011..Central venous catheter (CVC) placement increases the risk of thrombosis in cancer patients. Thrombosis often necessitates the removal of the CVC, resulting in treatment delays and thrombosis related morbidity and mortality... - Anticoagulation for the initial treatment of venous thromboembolism in patients with cancerElie A Akl
Department of Medicine, State University of New York at Buffalo, ECMC CC 142, 462 Grider Street, Buffalo, NY, USA, 14215
Cochrane Database Syst Rev 2:CD006649. 2011..Compared to patients without cancer, patients with cancer who receive anticoagulant treatment for venous thromboembolism are more likely to develop recurrent venous thromboembolism (VTE)... - Anticoagulation for patients with cancer and central venous cathetersElie A Akl
Department of Medicine, State University of New York at Buffalo, ECMC CC 142, 462 Grider Street, Buffalo, NY, USA, 14215
Cochrane Database Syst Rev 2:CD006468. 2011..Central venous catheter (CVC) placement increases the risk of thrombosis in cancer patients. Thrombosis often necessitates the removal of the CVC, resulting in treatment delays and thrombosis related morbidity and mortality... - Erythrocyte membrane phospholipid composition as a biomarker of dietary fatBarbara J Fuhrman
Department of Social and Preventive Medicine, University at Buffalo, State University of New York, Buffalo, NY 14214, USA
Ann Nutr Metab 50:95-102. 2006..05). CONCLUSIONS: Erythrocyte membrane levels of some specific fatty acids can be used as biomarkers of these fatty acids as proportions of dietary fat... - Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancerElie A Akl
Department of Medicine, State University of New York at Buffalo, ECMC CC 142, 462 Grider Street, Buffalo, NY, USA, 14215
Cochrane Database Syst Rev 6:CD006650. 2011..Cancer increases the risk of thromboembolic events even while on anticoagulation... - Parenteral anticoagulation may prolong the survival of patients with limited small cell lung cancer: a Cochrane systematic reviewElie A Akl
Department of Medicine, State University of New York at Buffalo, NY, USA
J Exp Clin Cancer Res 27:4. 2008..To determine the efficacy and safety of heparin (unfractionated heparin (UFH) or low-molecular-weight-heparin (LMWH)) and fondaparinux in improving the survival of patients with cancer... - An instrument to assess quality of life in relation to nutrition: item generation, item reduction and initial validationHolger J Schunemann
Department of Medicine, University at Buffalo, State University of New York, Buffalo, New York, USA
Health Qual Life Outcomes 8:26. 2010..Therefore, the aim of this project was to develop an instrument for measuring QoL related to nutrition in the general population... - Serum fructosamine and subsequent breast cancer risk: a nested case-control study in the ORDET prospective cohort studyMary Platek
Department of Exercise and Nutrition Sciences, University at Buffalo, State University of New York, 270 Farber Hall, 3435 Main Street, 14214 Buffalo, NY, USA
Cancer Epidemiol Biomarkers Prev 14:271-4. 2005..58 (95% CI, 0.76-3.40) and in postmenopausal women, the OR was 1.60 (95% CI, 0.76-3.48). Serum fructosamine levels tended to be positively associated with breast cancer risk independent of menopausal status... - Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulationElie A Akl
Department of Medicine, State University of New York at Buffalo, ECMC CC 142, 462 Grider Street, Buffalo, NY, USA, 14215
Cochrane Database Syst Rev 12:CD006466. 2010..A number of basic research and clinical studies have led to the hypothesis that oral anticoagulants may improve the survival of patients with cancer through an antitumor effect in addition to their antithrombotic effect... - Basal growth hormone concentrations in blood and the risk for prostate cancer: a case-control studyBarbara Fuhrman
Department of Social and Preventive Medicine, University at Buffalo, State University of New York, Buffalo, NY 14214, USA
Prostate 64:109-15. 2005..CONCLUSIONS: Lower basal levels of GH in serum are associated with increased prostate cancer risk. The inverse association may be explained by the negative feedback loop generated by IGF-1 produced by the tumor on GH secretion... - Low-molecular-weight heparin vs unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: a systematic review and meta-analysisElie A Akl
Department of Medicine, State University of New York at Buffalo, Erie County Medical Center CC 142, 462 Grider St, Buffalo, NY 14215, USA
Arch Intern Med 168:1261-9. 2008..We systematically reviewed the literature to quantify these effects... - Indicators of sexual and somatic development and adolescent body size in relation to prostate cancer risk: results from a case-control studyMaddalena Barba
Department of Epidemiology, Italian National Cancer Institute Regina Elena, Rome, Italy
Urology 72:183-7. 2008.... - Equol status modifies the association of soy intake and mammographic density in a sample of postmenopausal womenBarbara J Fuhrman
Department of Epidemiology, Italian National Cancer Institute Regina Elena, Via Elio Chianesi 53, Rome, Italy
Cancer Epidemiol Biomarkers Prev 17:33-42. 2008..5% in weekly soy consumers versus 30.7% in others; P = 0.03). Results suggest that equol producers and nonproducers may experience different effects of dietary soy on breast tissue...